Prognostic value of C-reactive protein levels in patients with cirrhosis

Liver Transplantation

Volumn 21, Issue 6, 2015, Pages 753-760

  Di Martino, Vincent ^a,b   Coutris, Caroline ^a   Cervoni, Jean Paul ^a   Dritsas, Stavros ^a,b   Weil, Delphine ^a   Richou, Carine ^a   Vanlemmens, Claire ^a   Thevenot, Thierry ^a,b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; CHILD PUGH SCORE; COMORBIDITY; FEMALE; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; BLOOD; EPIDEMIOLOGY; FRANCE; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; VALIDATION STUDY;

BIOMARKERS; C-REACTIVE PROTEIN; FEMALE; FRANCE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 84930047090     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24088     Document Type: Article

References (29)

1. Cervoni JP, Thévenot T, Weil D, Muel E, Barbot O, Sheppard F, et al., C-reactive protein predicts short-term mortality in patients with cirrhosis. J Hepatol 2012; 56: 1299-1304.
2. D'Amico G, Garcia-Tsao G, Pagliaro L,. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-231.
3. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al.,; for United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96.
4. Malik R, Mookerjee RP, Jalan R,. Infection and inflammation in liver failure: two sides of the same coin. J Hepatol 2009; 51: 426-429.
5. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
6. Navasa M, Follo A, Filella X, Jiménez W, Francitorra A, Planas R, et al., Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998; 27: 1227-1232.
7. Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-Khac E, et al., Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007; 46: 1872-1882.
8. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R,. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32 (pt 1): 734-739.
9. Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, et al., Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol 2011; 54: 640-649.
10. Charlson M, Szatrowski TP, Peterson J, Gold J,. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-1251.
11. Arvaniti V, D'Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, Burroughs AK,. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-1256.
12. Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F,. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol 2009; 51: 475-482.
13. Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, et al., Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996; 110: 1847-1853.
14. Navasa M, Rimola A, Rodés J,. Bacterial infections in liver disease. Semin Liver Dis 1997; 17: 323-333.
15. Mookerjee RP, Malaki M, Davies NA, Hodges SJ, Dalton RN, Turner C, et al., Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology 2007; 45: 62-71.
16. Cirera I, Bauer TM, Navasa M, Vila J, Grande L, Taurá P, et al., Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34: 32-37.
17. Shindo K, Machida M, Miyakawa K, Fukumura M,. A syndrome of cirrhosis, achlorhydria, small intestinal bacterial overgrowth, and fat malabsorption. Am J Gastroenterol 1993; 88: 2084-2091.
18. Garcia-Tsao G, Wiest R,. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004; 18: 353-372.
19. Viggiano TR, Gostout CJ,. Portal hypertensive intestinal vasculopathy: a review of the clinical, endoscopic, and histopathologic features. Am J Gastroenterol 1992; 87: 944-954.
20. Stanley AJ, Gilmour HM, Ghosh S, Ferguson A, McGilchrist AJ,. Transjugular intrahepatic portosystemic shunt as a treatment for protein-losing enteropathy caused by portal hypertension. Gastroenterology 1996; 111: 1679-1682.
21. Albillos A, Hera Ad Ade L, Reyes E, Monserrat J, Muñoz L, Nieto M, et al., Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin. J Hepatol 2004; 40: 624-631.
22. Saitoh O, Sugi K, Lojima K, Matsumoto H, Nakagawa K, Kayazawa M, et al., Increased prevalence of intestinal inflammation in patients with liver cirrhosis. World J Gastroenterol 1999; 5: 391-396.
23. Bellot P, García-Pagán JC, Francés R, Abraldes JG, Navasa M, Pérez-Mateo M, et al., Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology 2010; 52: 2044-2052.
24. Francés R, Muñoz C, Zapater P, Uceda F, Gascón I, Pascual S, et al., Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. Gut 2004; 53: 860-864.
25. Rosenbloom AJ, Pinsky MR, Bryant JL, Shin A, Tran T, Whiteside T,. Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS. Correlation with serum interleukin-6 levels and organ dysfunction. JAMA 1995; 274: 58-65.
26. Albillos A, de la Hera A, González M, Moya JL, Calleja JL, Monserrat J, et al., Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-217.
27. Bota DP, Van Nuffelen M, Zakariah AN, Vincent JL,. Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver. J Lab Clin Med 2005; 146: 347-351.
28. Ha YE, Kang CI, Joo EJ, Joung MK, Chung DR, Peck KR, et al., Usefulness of C-reactive protein for evaluating clinical outcomes in cirrhotic patients with bacteremia. Korean J Intern Med 2011; 26: 195-200.
29. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al.,; for CANONIC Study Investigators of the EASL-CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-1437.